Macitentan/Tadalafil

BRIDGEWATER, N.J., June 23, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced the appointment of Samuele Butera as Senior Vice President, General Manager, Global Respiratory, effective today. In this new role, Mr. Butera will assume responsibility for leading Insmed's Respiratory Therapeutic Area. Mr. Butera will report to Will Lewis, Chair and Chief Executive Officer, and serve as a member of Insmed's Executive Committee. "We are thrilled to welcome Samuele to Insmed," said Will Lewis, Chair and Chief Executive Officer of Insmed. "His depth of commercial expertise and proven ability to lead high-performing teams in some of the most complex and competitive therapeutic areas in our industry will be invaluable as he assumes leadership of our Respiratory Therapeutic Area. I am confident that Samuele's experience and passion for patients will be instrumental as we continue to execute on the launch of BRINSUPRI, the potential expansion of ARIKAYCE's label, and our broad TPIP development program." Mr. Butera joins Insmed with more than two decades of commercial leadership experience across global and U.S. markets. Most recently, he served as President, Pulmonary Hypertension & Retina, at Johnson & Johnson, where he led the significant growth of the multi-billion-dollar business unit and launch of OPSYNVI® (macitentan and tadalafil). While at Johnson & Johnson, he also served as Worldwide Vice President, Infectious Diseases & Vaccines, where he built the global commercial organization and co-led the company's expansion into vaccines (including COVID) and therapeutics. Prior to Johnson & Johnson, Mr. Butera held several senior leadership roles at Novartis, including Global Head of Cell & Gene Therapies, where he led the worldwide launch of KYMRIAH® (tisagenlecleucel), the first CAR-T therapy. He also served as Vice President & Head of Oncology CAR-T U.S. and as Vice President & Head of North America for Sandoz Biopharmaceuticals. Earlier in his career, Mr. Butera held roles at McKinsey & Company, Goldman Sachs, and the United Nations, providing him with a uniquely broad foundation across strategy, finance, and global health. Mr. Butera holds a Master in Public Policy from Harvard University and a Bachelor of Science in International Economics from Università Bocconi in Milan, Italy. "I am incredibly excited to join Insmed and lead the Respiratory Therapeutic Area at such a defining moment for the Company," said Mr. Butera. "Insmed has built a respiratory portfolio and pipeline that have the potential to meaningfully change the lives of patients. I look forward to working with the talented Insmed team to advance the already successful launch of BRINSUPRI, accelerate the growth of ARIKAYCE through the potential label expansion, and continue developing TPIP and other promising candidates for the patients who need them most." About Insmed Insmed Incorporated is a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases. The Company is advancing a diverse portfolio of approved and mid- to late-stage investigational medicines—including two approved therapies to treat chronic, debilitating lung diseases—as well as cutting-edge drug discovery focused on serving patient communities where the need is greatest. Insmed's commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology & Inflammation, and Neuro & Other Rare. The Company's research engine is advancing a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, RNA end-joining, and synthetic rescue, in the pursuit of future pipeline candidates. Headquartered in Bridgewater, New Jersey, Insmed has offices and research locations throughout the United States, Europe, and Japan. Insmed is proud to be recognized as one of the best employers in the biopharmaceutical industry, including spending five consecutive years as the No. 1 Science Top Employer. Visit  to learn more or follow us on LinkedIn, Instagram, YouTube, and X. Forward-looking Statements This press release contains forward-looking statements that involve substantial risks and uncertainties. "Forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995, are statements that are not historical facts and involve a number of risks and uncertainties. Words herein such as "may," "will," "should," "could," "would," "expects," "plans," "anticipates," "believes," "estimates," "projects," "predicts," "intends," "potential," "continues," and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) may identify forward-looking statements. The forward-looking statements in this press release are based upon the Company's current expectations and beliefs, and involve known and unknown risks, uncertainties and other factors, which may cause the Company's actual results, performance and achievements and the timing of certain events to differ materially from the results, performance, achievements or timings discussed, projected, anticipated or indicated in any forward-looking statements. Such risks, uncertainties and other factors include, among others, the following: failure to continue to successfully commercialize ARIKAYCE in the U.S., Europe or Japan or failure to successfully commercialize BRINSUPRI in the U.S. or Europe, or to maintain U.S., European or Japanese approval for ARIKAYCE or U.S. or European approval for BRINSUPRI; our inability to obtain full approval of ARIKAYCE from the FDA or our failure to obtain regulatory approval to expand ARIKAYCE's indication to a broader patient population; failure to obtain, or delays in obtaining, regulatory approvals for our product candidates in the U.S., Europe or Japan, for ARIKAYCE outside of the U.S., Europe and Japan, including separate regulatory approval for the Lamira® Nebulizer System in each market and for each usage, or for BRINSUPRI outside of the U.S. and Europe; failure to successfully conduct future clinical trials for our product candidates and our potential inability to enroll or retain sufficient patients to conduct and complete the trials or generate data necessary for regulatory approval of our product candidates; development of unexpected safety or efficacy concerns related to our marketed products or our product candidates; and risks that our clinical studies will be delayed, that serious side effects will be identified during drug development, or that any protocol amendments submitted will be rejected. The Company may not actually achieve the results, plans, intentions or expectations indicated by the Company's forward-looking statements because, by their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. For additional information about the risks and uncertainties that may affect the Company's business, please see the factors discussed in Item 1A, "Risk Factors," in the Company's Annual Report on Form 10-K for the year ended December 31, 2025 and any subsequent Company filings with the Securities and Exchange Commission (SEC). The Company cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date of this press release. The Company disclaims any obligation, except as specifically required by law and the rules of the SEC, to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Contact: Investors: Bryan Dunn Vice President, Investor Relations (646) 812-4030 [email protected] Media: Claire Mulhearn Vice President, Corporate Communications (862) 842-6819 [email protected] SOURCE Insmed Incorporated 21% more press release views with Request a Demo

BRIDGEWATER, N.J. 新泽西州布里奇沃特, ，June 23, 2026 2026年6月23日/PRNewswire/ -- Insmed Incorporated (Nasdaq: /美通社/ -- Insmed公司（纳斯达克：INSM INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced the appointment of Samuele Butera as Senior Vice President, General Manager, Global Respiratory, effective today. In this new role, Mr. ），一家以人为本的全球性生物制药公司，致力于提供首创和同类最佳的疗法，以改变患有严重疾病患者的生活，今日宣布任命萨穆埃莱·布特拉（Samuele Butera）为全球呼吸业务高级副总裁兼总经理，即日生效。在此新职位上，布特拉先生Butera will assume responsibility for leading Insmed's Respiratory Therapeutic Area. Mr. Butera will report to Will Lewis, Chair and Chief Executive Officer, and serve as a member of Insmed's Executive Committee.. 布特拉将负责领导Insmed公司的呼吸治疗领域。布特拉先生将向董事长兼首席执行官威尔·刘易斯汇报，并担任Insmed公司执行委员会成员。'We are thrilled to welcome Samuele to Insmed,' said Will Lewis, Chair and Chief Executive Officer of Insmed. 'His depth of commercial expertise and proven ability to lead high-performing teams in some of the most complex and competitive therapeutic areas in our industry will be invaluable as he assumes leadership of our Respiratory Therapeutic Area. Insmed公司董事长兼首席执行官威尔·刘易斯表示：“我们非常高兴萨穆埃莱加入Insmed。在他出任呼吸治疗领域负责人之际，其深厚的商业专业知识以及在行业内一些最复杂、竞争最激烈的治疗领域中领导高绩效团队的 proven 能力，将具有不可估量的价值。”I am confident that Samuele's experience and passion for patients will be instrumental as we continue to execute on the launch of BRINSUPRI, the potential expansion of ARIKAYCE's label, and our broad TPIP development program.'. 我相信，萨穆埃莱的经验以及对患者的热忱，将在我们持续推进BRINSUPRI的上市、拓展ARIKAYCE的适应症标签，以及实施广泛的TPIP开发计划的过程中发挥关键作用。Mr. Butera joins Insmed with more than two decades of commercial leadership experience across global and U.S. markets. Most recently, he served as President, Pulmonary Hypertension & Retina, at Johnson & Johnson, where he led the significant growth of the multi-billion-dollar business unit and launch of OPSYNVI® (macitentan and tadalafil). 布特拉先生加入Insmed公司，带来了在全球及美国市场逾二十年的商业领导经验。此前，他曾在强生公司担任肺动脉高压与视网膜业务总裁，期间带领该价值数十亿美元的业务部门实现显著增长，并成功推动OPSYNVI®（马昔腾坦与他达拉非）的上市。While at Johnson & Johnson, he also served as Worldwide Vice President, Infectious Diseases & Vaccines, where he built the global commercial organization and co-led the company's expansion into vaccines (including COVID) and therapeutics.. 在强生公司任职期间，他还担任全球传染病与疫苗副总裁，负责组建全球商业组织，并共同领导公司向疫苗（包括新冠疫苗）和治疗领域拓展。Prior to Johnson & Johnson, Mr. Butera held several senior leadership roles at Novartis, including Global Head of Cell & Gene Therapies, where he led the worldwide launch of KYMRIAH® (tisagenlecleucel), the first CAR-T therapy. He also served as Vice President & Head of Oncology CAR-T U.S. and as Vice President & Head of North America for Sandoz Biopharmaceuticals. 在加入强生公司之前，布特拉先生在诺华公司担任过多个高级领导职务，包括全球细胞与基因疗法负责人，期间他领导了首款CAR-T疗法KYMRIAH®（替沙仑赛）的全球上市。他还曾担任诺华肿瘤CAR-T美国业务副总裁兼负责人，以及山德士生物制药北美区副总裁兼负责人。Earlier in his career, Mr. Butera held roles at McKinsey & Company, Goldman Sachs, and the United Nations, providing him with a uniquely broad foundation across strategy, finance, and global health. Mr. Butera holds a Master in Public Policy from Harvard University and a Bachelor of Science in International Economics from Università Bocconi in Milan, Italy.. 在职业生涯早期，布特拉先生曾在麦肯锡公司、高盛集团和联合国任职，这使他在战略、金融和全球健康领域拥有了独特而广泛的基础。布特拉先生拥有哈佛大学公共政策硕士学位，以及意大利米兰博科尼大学国际经济学理学学士学位。'I am incredibly excited to join Insmed and lead the Respiratory Therapeutic Area at such a defining moment for the Company,' said Mr. Butera. 'Insmed has built a respiratory portfolio and pipeline that have the potential to meaningfully change the lives of patients. I look forward to working with the talented Insmed team to advance the already successful launch of BRINSUPRI, accelerate the growth of ARIKAYCE through the potential label expansion, and continue developing TPIP and other promising candidates for the patients who need them most.'. “在公司如此具有里程碑意义的时刻加入Insmed并领导呼吸治疗领域，我感到无比兴奋。”布特拉先生表示，“Insmed已建立起一个有望显著改善患者生活的呼吸产品组合及研发管线。我期待与才华横溢的Insmed团队携手，推动BRINSUPRI已经成功的上市工作进一步取得进展，通过潜在的适应症扩展加速ARIKAYCE的增长，并继续开发TPIP及其他有前景的候选药物，以惠及最需要的患者。”About Insmed 关于InsmedInsmed Incorporated is a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases. The Company is advancing a diverse portfolio of approved and mid- to late-stage investigational medicines—including two approved therapies to treat chronic, debilitating lung diseases—as well as cutting-edge drug discovery focused on serving patient communities where the need is greatest. Insmed Incorporated 是一家以人为本的全球性生物制药公司，致力于提供首创新药和同类最优疗法，以改变患有严重疾病患者的生活。公司正在推进一个多样化的产品组合，包括已获批的药物以及处于中后期临床试验阶段的在研药物——其中包含两款用于治疗慢性、致残性肺部疾病的获批疗法——同时开展前沿的药物研发工作，专注于服务需求最为迫切的患者群体。Insmed's commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology & Inflammation, and Neuro & Other Rare. The Company's research engine is advancing a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, RNA end-joining, and synthetic rescue, in the pursuit of future pipeline candidates.. Insmed的商业产品组合和临床管线围绕三个治疗领域进行组织：呼吸系统、免疫学与炎症，以及神经与其他罕见病。公司的研发引擎正在推进广泛的技术和治疗模式，包括基因疗法、人工智能驱动的蛋白质工程、RNA末端连接以及合成救援，以开发未来的管线候选药物。Headquartered in Bridgewater, New Jersey, Insmed has offices and research locations throughout the United States, Europe, and Japan. Insmed is proud to be recognized as one of the best employers in the biopharmaceutical industry, including spending five consecutive years as the No. 1 Science Top Employer. Insmed 总部位于新泽西州布里奇沃特，在美国、欧洲和日本设有办事处和研发中心。Insmed 很自豪地被评为生物制药行业最佳雇主之一，并连续五年荣登《科学》杂志“顶级雇主”榜首。Visit . 访问。www.insmed.com www.insmed.comto learn more or follow us on 了解更多或关注我们LinkedIn 领英, ，Instagram Instagram, ，YouTube YouTube, and ，和X X. 。Forward-looking Statements 前瞻性陈述This press release contains forward-looking statements that involve substantial risks and uncertainties. 'Forward-looking statements,' as that term is defined in the Private Securities Litigation Reform Act of 1995, are statements that are not historical facts and involve a number of risks and uncertainties. 本新闻稿包含涉及重大风险和不确定性的前瞻性陈述。根据1995年《私人证券诉讼改革法》的定义，“前瞻性陈述”是指非历史事实的陈述，并涉及多种风险和不确定性。Words herein such as 'may,' 'will,' 'should,' 'could,' 'would,' 'expects,' 'plans,' 'anticipates,' 'believes,' 'estimates,' 'projects,' 'predicts,' 'intends,' 'potential,' 'continues,' and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) may identify forward-looking statements.. 本文中的“可能”、“将”、“应当”、“可以”、“会”、“预期”、“计划”、“预计”、“相信”、“估计”、“规划”、“预测”、“打算”、“潜在”、“持续”等词语以及类似表述（以及其他提及未来事件、条件或情况的词语或表述）可能用于识别前瞻性陈述。The forward-looking statements in this press release are based upon the Company's current expectations and beliefs, and involve known and unknown risks, uncertainties and other factors, which may cause the Company's actual results, performance and achievements and the timing of certain events to differ materially from the results, performance, achievements or timings discussed, projected, anticipated or indicated in any forward-looking statements. 本新闻稿中的前瞻性陈述基于公司当前的预期和信念，涉及已知和未知的风险、不确定性及其他因素，这些因素可能导致公司的实际结果、表现和成就以及某些事件的发生时间与任何前瞻性陈述中讨论、预测、预期或指示的结果、表现、成就或时间存在重大差异。Such risks, uncertainties and other factors include, among others, the following: failure to continue to successfully commercialize ARIKAYCE in the U.S., Europe or Japan or failure to successfully commercialize BRINSUPRI in the U.S. or Europe, or to maintain U.S., European or Japanese approval for ARIKAYCE or U.S. 此类风险、不确定性和其他因素包括但不限于以下各项：未能继续在美国、欧洲或日本成功实现ARIKAYCE的商业化，或未能在美国或欧洲成功实现BRINSUPRI的商业化，或未能维持ARIKAYCE在美国、欧洲或日本的批准，或美国。or European approval for BRINSUPRI; our inability to obtain full approval of ARIKAYCE from the FDA or our failure to obtain regulatory approval to expand ARIKAYCE's indication to a broader patient population; failure to obtain, or delays in obtaining, regulatory approvals for our product candidates in the U.S., Europe or Japan, for ARIKAYCE outside of the U.S., Europe and Japan, including separate regulatory approval for the Lamira® Nebulizer System in each market and for each usage, or for BRINSUPRI outside of the U.S. 或未能获得欧洲对BRINSUPRI的批准；我们未能获得美国食品药品监督管理局（FDA）对ARIKAYCE的完全批准，或未能获得监管批准以将ARIKAYCE的适应症扩展至更广泛的患者群体；未能在美国、欧洲或日本获得我们的候选产品的监管批准，或未能在美国、欧洲和日本以外的地区获得ARIKAYCE的监管批准（包括在每个市场及每种用途下分别获得Lamira®雾化器系统的监管批准），或未能在美国以外地区获得BRINSUPRI的监管批准；或上述监管批准的获取出现延迟。and Europe; failure to successfully conduct future clinical trials for our product candidates and our potential inability to enroll or retain sufficient patients to conduct and complete the trials or generate data necessary for regulatory approval of our product candidates; development of unexpected safety or efficacy concerns related to our marketed products or our product candidates; and risks that our clinical studies will be delayed, that serious side effects will be identified during drug develop. 以及欧洲；未能成功开展针对我们候选产品的未来临床试验，且我们可能无法招募或保留足够的患者以开展并完成试验，或无法生成监管审批我们候选产品所需的数据；出现与我们已上市产品或候选产品相关的意想不到的安全性或有效性问题；以及我们的临床研究可能延迟、在药物开发过程中发现严重副作用的风险。The Company may not actually achieve the results, plans, intentions or expectations indicated by the Company's forward-looking statements because, by their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. 公司可能无法实际实现其前瞻性陈述所指示的结果、计划、意图或预期，因为前瞻性陈述就其性质而言涉及风险和不确定性，因其与未来可能发生也可能不发生的事件相关，并取决于未来可能出现也可能不出现的情况。For additional information about the risks and uncertainties that may affect the Company's business, please see the factors discussed in Item 1A, 'Risk Factors,' in the Company's Annual Report on Form 10-K for the year ended December 31, 2025 and any subsequent Company filings with the Securities and Exchange Commission (SEC).. 有关可能影响本公司业务的风险和不确定性的更多信息，请参阅本公司截至2025年12月31日止年度的10-K表年度报告中第1A项“风险因素”所讨论的因素，以及本公司随后向美国证券交易委员会（SEC）提交的任何文件。The Company cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date of this press release. The Company disclaims any obligation, except as specifically required by law and the rules of the SEC, to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.. 本公司提醒读者，不要过度依赖任何此类前瞻性陈述，这些陈述仅在本新闻稿发布之日有效。除法律和证券交易委员会（SEC）规则明确要求外，本公司不承担任何公开更新或修订任何此类陈述的义务，以反映预期变化，或反映任何此类陈述所依据的事件、条件或情况的变化，或可能影响实际结果与前瞻性陈述中所述结果存在差异的可能性的变化。Contact: 联系方式：Investors: 投资者：Bryan Dunn 布莱恩·邓恩Vice President, Investor Relations 副总裁，投资者关系(646) 812-4030 (646) 812-4030[emailprotected] [email protected]Media: 媒体：ClaireMulhearn 克莱尔·穆赫恩Vice President, Corporate Communications 副总裁，企业传播(862) 842-6819 (862) 842-6819[emailprotected] [email protected]SOURCE Insmed Incorporated 来源：Insmed Incorporated21 二十一% %more press release views with 更多新闻稿浏览量与Request a Demo 申请演示